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ABSTRACT 
 
Mycoplasma hyopneumoniae is a respiratory pathogen of pigs that has substantial global 
economic impact and currently there is no vaccine available that prevents colonisation. 
This study focuses on the characterisation of novel M. hyopneumoniae vaccine candidates 
and the development of a live, attenuated vaccine expressing heterologous M. 
hyopneumoniae antigens. The putative M. hyopneumoniae vaccine antigen, the lipoyl 
binding domain of the dihydrolipoyl dehydrogenase subunit (PdhD) of the pyruvate 
dehydrogenase complex, was strongly recognised by porcine hyperimmune sera. Western 
blot analysis with PdhD antisera detected the protein in geographically diverse M. 
hyopneumoniae isolates. However PdhD was only weakly recognised by convalescent 
swine sera indicating it is not likely to contribute significantly to the protective 
convalescent response. Therefore it was not used in further vaccination experiments. Live 
vaccine delivery systems expressing two antigens from M. hyopneumoniae, adhesin 
(Adh) and ribonucleotide reductase (NrdF), were constructed using either plasmid-based 
expression (PBE) or chromosomally-based expression (CBE) systems.  The PBE system 
was formed by cloning both antigen genes into pJLA507 to create an operon downstream 
of temperature-inducible promoters. Constitutive CBE was achieved using a promoter 
trapping technique whereby the promoterless operon was stably integrated into the 
chromosome of Salmonella enterica serovar Typhimurium aroA (STM-1) and the 
expression of antigens assessed. The chromosomal position of the operon was mapped in 
four clones. Inducible CBE was obtained using the in vivo induced sspA promoter and 
recombining the expression construct into aroD. Dual expression of the antigens was 
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detected in all systems with PBE producing much higher quantities of both antigens. The 
stability of antigen expression was higher in the CBE system with 60-100% of individual 
cells still expressing antigen after 60 generations without selection. PBE and CBE strains 
were selected for comparison in a vaccination trial. The vaccine strains were delivered 
orally into mice and significant systemic IgM and IgG responses against both antigens 
amongst all CBE groups were detected. No significant immune response against either 
antigen was detected using PBE strains. Expression of recombinant antigens in S. 
enterica serovar Typhimurium aroA from chromosomally-located strong promoters 
without the use of antibiotic resistance markers is a reliable and effective method of 
inducing a significant immune response. 
 
 
 
